Management to host webcast and conference call on August 10, 2016 at 1:15 p.m. PDT/4:15 p.m. EDT LA JOLLA, Calif. , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced it will report second quarter 2016 financial results
LA JOLLA, Calif. , June 16, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced the first patient has been dosed in a Phase 2 clinical trial of tipifarnib in patients with lower risk myelodysplastic syndromes (MDS).
LA JOLLA, Calif. , June 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 JMP Life Sciences Conference . Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will participate in a
LA JOLLA, Calif. , June 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the Jefferies 2016 Healthcare Conference. Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to
LA JOLLA, Calif. , May 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (NASDAQ:KURA) a clinical stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2016 . “Kura has made important progress in advancing its pipeline of precision oncology drug
Management to Host Webcast and Conference Call Today at 4:30 p.m. EDT LA JOLLA, Calif. , March 17, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (NASDAQ:KURA) a clinical stage biopharmaceutical company, today announced highlights and financial results for the fourth quarter and full year ended
LA JOLLA, Calif. , March 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that it will report fourth quarter and full year 2015 financial results after the close of U.S. financial markets on March 17, 2016 .
LA JOLLA, Calif. , Feb. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at 2:15 p.m. ET ( 11:15 a.m.
Tipifarnib as Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients With High Risk Disease LA JOLLA, Calif. , Dec. 3, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that new data from
LA JOLLA, Calif. , Dec. 1, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 10:55 a.m. EST ( 7:55 a.m.
